FDA 483 - Norbitec GmbH - April 06, 2023

Norbitec GmbH, a drug substance manufacturer in Uetersen, Germany, received four observations during an FDA inspection. The observations detail significant deficiencies in quality oversight, cleaning procedures, validation activities for manufacturing processes and equipment, and the maintenance of facility systems. These issues collectively indicate a lack of control over critical aspects of drug substance production.